Novelix Pharmaceuticals Limited has re-appointed M/s V R P S & Co. Chartered Accountants as its internal auditor for the financial year 2026-27. The board approved the re-appointment at its meeting held on May 29, 2026, to ensure compliance with the Companies Act, 2013 and the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The firm, bearing registration number 006340S, was selected to provide a wide spectrum of services across sectors with a focus on result-oriented solutions. The disclosure confirms that the auditor is not related to any of the directors, key managerial personnel, or their relatives.

The board meeting, which commenced at 05:00 P.M. and concluded at 06:30 P.M., was conducted under Regulation 30 of the SEBI (LODR) Regulations. The re-appointment is effective immediately for the specified financial year.

Internal Auditor Details

Novelix Pharmaceuticals Limited has submitted its quarterly compliance certificate under SEBI (Depositories and Participants) Regulations, 2018 to BSE Limited for the quarter ended March 31, 2026. The certificate demonstrates the company's adherence to mandatory regulatory requirements for securities dematerialisation processes.

Regulatory Compliance Certificate

The certificate was issued by Venture Capital and Corporate Investments Private Limited, serving as the company's Registrar and Share Transfer Agent (R&T Agent). The document was submitted to BSE Limited on April 9, 2026, and signed by Venkateshwarlu Pulluru, Whole-time Director of Novelix Pharmaceuticals Limited.

Dematerialisation Process Confirmation

The R&T Agent certified that securities received for dematerialisation have been properly mutilated and cancelled after due verification. The certificate confirms that the names of both depositories - National Securities Depository Limited (NSDL) and Central Depository Services (India) Limited (CDSL) - have been updated in the company's records as registered owners within the mandated 15-day period.

The certification process ensures that valid Dematerialisation Request Forms (DRF) and share certificates were processed according to regulatory guidelines. Details of the securities have been furnished to the relevant stock exchanges as required under the regulations.

Company Information

Novelix Pharmaceuticals Limited, formerly known as Trimurthi Limited , operates from its registered office in Hyderabad, Telangana. The company maintains its corporate identification number as L67120TG1994PLC018956 and trades under the scrip symbol NOVELIX on stock exchanges.

The submission of this quarterly certificate represents standard regulatory compliance, ensuring transparency in the dematerialisation process and maintaining accurate depository records for investor protection.